Emerging nanoparticulate drug delivery systems of metformin
- PDF / 1,454,338 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 61 Downloads / 239 Views
Journal of Pharmaceutical Investigation https://doi.org/10.1007/s40005-020-00480-1
REVIEW
Emerging nanoparticulate drug delivery systems of metformin Yao Chen1 · Xinzhu Shan1 · Cong Luo1 · Zhonggui He1 Received: 8 February 2020 / Accepted: 31 March 2020 © The Korean Society of Pharmaceutical Sciences and Technology 2020
Abstract Background Driving the conventional drug in new applications has emerged as a research hotspot for disease treatment. Metformin (MET) is conventionally used for the treatment of type II diabetes. It has also been found to be a versatile molecule with wide biological functions, such as losing weight. anti-aging and anticancer activity. Rational design of nanoparticulate drug delivery systems (nano-DDS) could significantly improve drug delivery efficiency. Recently, a wide range of nanoDDS has been developed to improve the delivery efficacy of MET or to perform as versatile nanoplatforms for efficient drug delivery. Area covered In this review, we outline the emerging trends in advanced nano-DDS of MET, focusing on nano-DDS of MET for diabetes therapy, nano-DDS of MET for anticancer therapeutics, and nano-DDS of MET for other therapeutic aims. Expert opinion Despite the great progression in nano-DDS of MET, there’s still a long way to truly put the conventional drug in new applications. Several important issues should be fully taken into consideration, such the manufacturing cost and economic burdens for patients, the biocompatibility and long-term toxicity of carrier materials, scale-up preparation difficulties, as well as the species gap between human beings and animal models. Keywords MET · Nano-DDS · Diabetes · Anticancer · Versatile treatments
Introduction Conventional drug in new applications has provided more versatile therapeutic options for clinical treatment of diseases (Baker et al. 2018). Among them, metformin (MET, dimethylbiguanide) has attracted considerable attention as a promising therapeutic agent for multiple diseases in recent years (Wang et al. 2017). MET is traditionally used for treatment of type II diabetes mellitus (Wang et al. 2017; Shurrab and Arafa 2020). MET, a cationic drug with a daily dose as high as several grams, which demonstrates well established efficacy and little toxicity (Wang et al. 2017; Shurrab and Arafa 2020). More interestingly, it has also been found to have multiple biological functions, such as losing weight, anti-aging and anticancer activity (Wang et al. 2017; Shurrab * Cong Luo [email protected] * Zhonggui He [email protected] 1
Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, People’s Republic of China
and Arafa 2020). Particularly, patients with diabetes mellitus are at higher risk of cancer, MET has been found to demonstrate significant antitumor activity against a wide range of cancers (Samuel et al. 2019; Yu et al. 2019). Due to its cationic structure, the in vivo biomedical process of MET is significantly affected by organic cation transpo
Data Loading...
